Related Experiment Video
Updated: Jul 26, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)]
Abstract:
With the development of precision diagnosis and treatment for non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, as a rare subset of EGFR mutaions, have gradually attracted attention recently. The heterogeneity of EGFR ex20ins mutations is very high, different variants have different clinical benefits, and the prognosis is extremely poor. The available traditional treatment outcomes are poor in patients with EGFR ex20ins positive NSCLC and polymerase chain reaction (PCR) tests would miss aprocimately 50% of the variants. Therefore, high attention should be paid to EGFR ex20ins positive NSCLC during the clinical practice. The expert panel has formed a consensus on the standardized clinical diagnosis and treatment of EGFR ex20ins mutation NSCLC through reference to literature and clinical data, and combined with the experts' own clinical experience, the consensus recommendations including clinicopathologic characteristics, therapies, testing methods and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation, in order to provide medication reference for clinical physicians at all levels.
Insights
Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC) are rare but aggressive. This consensus provides guidance on diagnosis, treatment, and testing for these challenging mutations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Non-small cell lung cancer (NSCLC) treatment advances highlight rare EGFR exon 20 insertion (ex20ins) mutations.
- EGFR ex20ins mutations present significant heterogeneity, poor prognosis, and limited treatment efficacy.
- Conventional diagnostic methods like PCR miss a substantial proportion of EGFR ex20ins variants.
Purpose:
- To establish a consensus on standardized clinical diagnosis and treatment strategies for NSCLC patients with EGFR ex20ins mutations.
- To provide evidence-based recommendations for physicians managing this specific NSCLC subset.
- To consolidate current knowledge on clinicopathologic characteristics, therapeutic options, and testing methodologies.
Summary:
- Expert panel consensus addresses the challenges posed by heterogeneous EGFR ex20ins mutations in NSCLC.
- Recommendations cover diagnosis, molecular testing, treatment modalities, and emerging clinical trials.
- Focus on improving outcomes for patients with this poor-prognosis NSCLC subtype.
Impact:
- Aims to improve clinical decision-making and patient outcomes for EGFR ex20ins NSCLC.
- Facilitates standardized approaches to diagnosis and treatment, addressing current limitations.
- Offers a valuable reference for healthcare professionals in managing this rare but critical mutation.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
